“Prophylactic Tocilizumab May Prevent Cytokine Release Syndrome in Teclistamab Cancer Treatment: Study Reveals Conflicts of Interest with Pharmaceutical Companies”

https://pubmed.ncbi.nlm.nih.gov/38114481

This study suggests that prophylactic tocilizumab may help prevent cytokine release syndrome (CRS) in patients receiving teclistamab for blood cancer, but conflicts of interest exist among the authors due to ties with pharmaceutical companies involved in cancer treatment.